Niramai

Executive Summary

Niramai is a UK-based medtech company revolutionizing breast cancer screening with its AI-powered, non-invasive Thermalytix platform. Founded in 2016, the company leverages proprietary machine learning algorithms on thermal imaging to detect early-stage breast cancer without radiation or physical contact. With FDA clearance, Niramai has deployed its devices in over 200 hospitals across 30+ cities and screened more than 300,000 women, demonstrating strong clinical adoption and scalability. The technology addresses critical gaps in traditional screening—such as radiation exposure, discomfort, and limited accessibility—making it particularly suitable for low-resource settings and younger demographics. By combining artificial intelligence with cost-effective thermal sensors, Niramai offers a portable, radiation-free alternative to mammography, potentially expanding breast cancer screening globally. Niramai's growth trajectory is supported by its validated technology, regulatory approvals, and expanding commercial footprint. The company is well-positioned to capture market share in the global breast cancer diagnostics market, which is driven by increasing awareness and demand for non-invasive screening methods. Future catalysts include potential CE marking for European expansion, new clinical validation studies in varied populations, and strategic partnerships with healthcare systems. While competition from established screening modalities exists, Niramai's unique value proposition and early traction suggest strong upside. The company remains private, but its demonstrated outcomes and clear market need underpin a favorable risk-reward profile for investors.

Upcoming Catalysts (preview)

• Q1 2027CE Mark Approval for European Market Entry60% success
• Q4 2026Publication of Large-Scale Clinical Validation Study70% success
• Q3 2026Strategic Partnership with Major US Hospital Network50% success